ALPMY
Astellas Pharma Inc.
Set alert
- YTD
- +21.60%
- 1 year
- +48.26%
- Open
- 16.18
- Prev close
- 16.00
- Mkt cap
- 28.98B
- Vol
- 6.47K
- Avg vol
- 100.28K
- EPS
- 1.33
- P/E
- 12.15
More statistics
- Low
- 16.13
- High
- 16.19
- Earnings
- Oct 29, 2026
News
1 week ago zacks.com
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
Here is how Elevance Health (ELV) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
1 week ago defenseworld.net
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both large-cap healthcare companies, but which is the better business? We will compare the…
2 weeks ago defenseworld.net
Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s What Happened
Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) gapped down before the market opened on Monday. The stock had previously closed at $14.20, but opened at $13.48. Astellas Pharma…
2 weeks ago defenseworld.net
Astellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9%
Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest…
1 month ago benzinga.com
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
1 month ago zacks.com
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
2 months ago defenseworld.net
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) and Kyowa Kirin (OTCMKTS:KYKOF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
2 months ago zacks.com
New Strong Sell Stocks for August 19th
ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.
2 months ago seekingalpha.com
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata…
2 months ago zacks.com
New Strong Sell Stocks for August 6th
COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026.
3 months ago benzinga.com
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
4 months ago zacks.com
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
4 months ago zacks.com
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
4 months ago zacks.com
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
4 months ago zacks.com
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
4 months ago seekingalpha.com
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
5 months ago gurufocus.com
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos
5 months ago zacks.com
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
5 months ago zacks.com
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year.
6 months ago seekingalpha.com
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
6 months ago zacks.com
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
6 months ago zacks.com
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
8 months ago benzinga.com
These Analysts Boost Their Forecasts On Vir Biotechnology
These Analysts Boost Their Forecasts On Vir Biotechnology
8 months ago benzinga.com
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.
8 months ago benzinga.com
Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why
Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, and upbeat earnings boost outlook.
10 months ago benzinga.com
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
1 year ago benzinga.com
Why Is Taysha Gene Therapies Stock Falling Friday?
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
-
2 years ago benzinga.com
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
-
3 years ago benzinga.com
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Thursday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
6 years ago benzinga.com
The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday